U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266545) titled 'RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)' on Nov. 25.
Brief Summary: The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.
Study Start Date: Dec. 31
Study Type: INTERVENTIONAL
Condition:
Unipolar Depression
Bipolar Depression
Intervention:
DRUG: Vortioxetine
Vortioxetine, once daily, for 8 weeks
DRUG: Bupropion extended release
Bupropion extended release, once daily, for 8 weeks
DRUG: Cariprazine (Augmentation Phase)
Participants who do not meet remission criteria will enter a sec...